Malignant Colorectal Neoplasm
Associated Genetic Biomarkers
Malignant colorectal neoplasms most frequently harbor alterations in TP53, APC, KRAS, PIK3CA, and SMAD4 .
TP53 Mutation, APC Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and KRAS Mutation are the most common alterations in malignant colorectal neoplasm .
There are 2 clinical trials for malignant colorectal neoplasm, of which 1 is open and 1 is completed or closed. Of the trials that contain malignant colorectal neoplasm as an inclusion criterion, 1 is phase 1 (1 open) and 1 is no phase specified (0 open).
Deficient, HLA-A*11:01, and HLA-C*08:02 are the most frequent gene inclusion criteria for malignant colorectal neoplasm clinical trials .
V941 and pembrolizumab are the most common interventions in malignant colorectal neoplasm clinical trials.
Significant Genes in Malignant Colorectal Neoplasm
KRAS is altered in 40.06% of malignant colorectal neoplasm patients .
KRAS is an inclusion eligibility criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant colorectal neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.